Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab

Mark Lebwohl; Andrew Blauvelt; Alan Menter; Kim Papp; Abby Jacobson

doi:10.25251/skin.3.supp.26

Mark Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Alan Menter

Baylor University Medical Center, Dallas, TX, USA

Kim Papp

Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada

Abby Jacobson

Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ, USA

Keywords

psoriasis, brodalumab

Abstract

Abstract not available.

References

1. Papp et al. N Engl J Med. 2012;366:1181-1189.

2. Papp et al. J Am Acad Dermatol. 2014;71:1183-1190.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.26

How to Cite

Lebwohl, M., Blauvelt, A., Menter, A., Papp, K., & Jacobson, A. (2019). Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab. SKIN The Journal of Cutaneous Medicine, 3, S26. https://doi.org/10.25251/skin.3.supp.26

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Linda Stein Gold, Mark Lebwohl, Robert Bissonnette, Bruce Strober, Anna M Tallman, Philip M Brown, Stephen C Piscitelli, David S Rubenstein, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichnfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk, Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan I Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis, Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Kristian Reich, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, Andrew Blauvelt, Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard Warren, Kristian Reich, Eric Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Anna Carlsson, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt, 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Kim A Papp, Andrew Blauvelt, John Sullivan, Et al., Efficacy of Ixekizumab in Patients Previously Treated with IL-17 Inhibitors , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Lawrence Green, Miriam Bettencourt, Scott Fretzin, Abby Jacobson, Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, Andrew Blauvelt, Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Ronald Prussick, Mark Lebwohl, Nadege Gunn, Susan Harris, Jason Vittitow, Abby Jacobson, Robert J Israel, Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Kristian Reich, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, Andrew Blauvelt, Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

<< < 9 10 11 12 13 14 15 16 17 18 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)